Articles with "000 per" as a keyword



Photo by aaronburden from unsplash

Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Neurology"

DOI: 10.1007/s00415-018-8835-6

Abstract: IntroductionAcquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of… read more here.

Keywords: incidence; 000 per; study; 100 000 ... See more keywords
Photo from wikipedia

P103 The impact of the COVID-19 pandemic on primary care referrals and new diagnoses of inflammatory arthritis

Sign Up to like & get
recommendations!
Published in 2023 at "Rheumatology"

DOI: 10.1093/rheumatology/kead104.144

Abstract: The COVID-19 pandemic abruptly changed healthcare delivery. This study describes the impact the pandemic had on time to referral and diagnosis of inflammatory arthropathies (IA), including rheumatoid arthritis (RA) and juvenile inflammatory arthritis (JIA), in… read more here.

Keywords: diagnosis; 000 per; covid; 000 000 ... See more keywords
Photo by nci from unsplash

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Sign Up to like & get
recommendations!
Published in 2022 at "Neurology"

DOI: 10.1212/wnl.0000000000013314

Abstract: Background and Objectives Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. The… read more here.

Keywords: cost; care; effectiveness; price ... See more keywords